Suppr超能文献

内源性内皮素-1在大鼠心脏缺血后心功能障碍及去甲肾上腺素外溢中的作用。

Role of endogenous endothelin-1 in post-ischemic cardiac dysfunction and norepinephrine overflow in rat hearts.

作者信息

Tawa Masashi, Fukumoto Taiki, Ohkita Mamoru, Matsumura Yasuo

机构信息

Laboratory of Pathological and Molecular Pharmacology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan.

出版信息

Eur J Pharmacol. 2008 Sep 4;591(1-3):182-8. doi: 10.1016/j.ejphar.2008.06.039. Epub 2008 Jun 14.

Abstract

Endothelin-1 and norepinephrine are involved in myocardial ischemia/reperfusion injury. The aim of this study was to investigate the role of endogenously generated endothelin-1 in ischemia/reperfusion-induced norepinephrine overflow and cardiac dysfunction using a nonselective prototype of endothelin-converting enzyme (ECE) inhibitor, phosphoramidon, and a selective ECE inhibitor, SM-19712 (4-chloro-N-[[(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)amino]carbonyl]benzenesulfonamide, monosodium salt). According to the Langendorff technique, isolated Sprague-Dawley rat hearts were subjected to 40-min global ischemia followed by 30-min reperfusion. Phosphoramidon and SM-19712 were perfused 30 min before ischemia and during reperfusion. Endothelin-1 level in left ventricle was increased by ischemia/reperfusion. This increase in left ventricular endothelin-1 level was suppressed by treatment with SM-19712. SM-19712 significantly improved ischemia/reperfusion-induced cardiac dysfunction such as decreased left ventricular developed pressure and dP/dt(max) and increased left ventricular end diastolic pressure. In addition, this agent suppressed excessive norepinephrine overflow in the coronary effluent from the post-ischemic heart. In contrast, treatment with phosphoramidon further enhanced left ventricular endothelin-1 level and norepinephrine overflow, and significantly worsened cardiac dysfunction after ischemia/reperfusion. These responses such as exaggerated norepinephrine overflow and the cardiac dysfunction observed after ischemia/reperfusion were markedly suppressed in the presence of a selective endothelin ET(A) receptor antagonist, ABT-627 [2R-(4-methoxyphenyl)-4S-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid]. These findings indicate that cardiac endothelin-1 production is enhanced by ischemia/reperfusion, and this endogenously increased endothelin-1 is involved in post-ischemic norepinephrine overflow and cardiac dysfunction via the activation of endothelin ET(A) receptors.

摘要

内皮素 -1 和去甲肾上腺素参与心肌缺血/再灌注损伤。本研究的目的是使用内皮素转换酶(ECE)抑制剂的非选择性原型磷酰胺素以及选择性 ECE 抑制剂 SM -19712(4 -氯 -N -[[(4 -氰基 -3 -甲基 -1 -苯基 -1H -吡唑 -5 -基)氨基]羰基]苯磺酰胺单钠盐),研究内源性生成的内皮素 -1 在缺血/再灌注诱导的去甲肾上腺素溢出和心脏功能障碍中的作用。根据 Langendorff 技术,将分离的 Sprague - Dawley 大鼠心脏进行 40 分钟的全心缺血,随后进行 30 分钟的再灌注。在缺血前 30 分钟和再灌注期间灌注磷酰胺素和 SM -19712。缺血/再灌注使左心室内皮素 -1 水平升高。用 SM -19712 处理可抑制左心室内皮素 -1 水平的这种升高。SM -19712 显著改善了缺血/再灌注诱导的心脏功能障碍,如左心室舒张末压降低、左心室压力上升最大速率(dP/dt(max))降低以及左心室舒张末期压力升高。此外,该药物抑制了缺血后心脏冠状动脉流出液中过量的去甲肾上腺素溢出。相比之下,用磷酰胺素处理进一步提高了左心室内皮素 -1 水平和去甲肾上腺素溢出,并显著加重了缺血/再灌注后的心脏功能障碍。在存在选择性内皮素 ET(A)受体拮抗剂 ABT -627 [2R - (4 -甲氧基苯基)-4S - (1,3 -苯并二氧杂环戊烯 -5 -基)-1 - (N,N -二(n -丁基)氨基羰基 -甲基)-吡咯烷 -3R -羧酸]的情况下,缺血/再灌注后观察到的诸如去甲肾上腺素溢出夸张和心脏功能障碍等反应明显受到抑制。这些发现表明,缺血/再灌注可增强心脏内皮素 -1 的产生,并且这种内源性增加的内皮素 -1 通过激活内皮素 ET(A)受体参与缺血后去甲肾上腺素溢出和心脏功能障碍。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验